Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Shaped by Brexit, driven by COVID, squeezed by budgets and being engineered for the future, it seems that almost every element within UK health delivery and market access is undergoing change. How should the medtech industry prepare, and will there be implications beyond the UK?
France’s Ipsen has taken an exclusive option on two neurodegenerative disease programs at US biotech Exicure, whose oligonucleotide nanoparticles are taken up by many tissues, including the brain.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation